Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Antibiotic-associated diarrhea due to Clostridium difficile (CDAD) is thought to reflect colonization of a disrupted microbial community by the pathogen. We profiled the fecal microbiota of patients with CDAD (both initial and recurrent episodes) by culture-independent phylogenetic analysis of 16S rRNA-encoding gene sequences. Compared with those from control subjects and patients with an initial episode, the fecal communities in patients with recurrent CDAD were highly variable in bacterial composition and were characterized by markedly decreased diversity. Preservation and restoration of the microbial diversity could represent novel strategies for prevention and treatment of recurrent CDAD, which is often recalcitrant to existing therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, a small, open label pilot study comparing upper and lower GI routes of administration did not show any differences44”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [44]
In the citing paper
“The human gut microbiota can restrict the growth of pathogens to prevent them from colonizing the intestine (‘colonization resistance’).”
From Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization (2023) · cites this paper as [28]
In the citing paper
“Gut microbiota with high diversity have higher colonization resistance than gut microbiota with low diversity as a result of antibiotic treatment [28].”
From Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization (2023) · cites this paper as [28]
Citations
Cites
Measuring biological diversity
(2004) · Choice Reviews Online · doi:10.5860/choice.42-1547 · Cited by 6,621
Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006) · Cell · doi:10.1016/j.cell.2006.02.017 · Cited by 3,358 · cited 3×
“exist in a complex symbiosis with their host [5].”
BackgroundInfluentialSchloss, P. D., & Handelsman, J. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.3.1501-1506.2005 · Cited by 2,501 · cited 1×
“The distance matrix was fed into DOTUR [8] to group the sequences into operational taxonomic units (OTUs), calculate ecological diversity measures (including the Shannon index [9]), and generate rarefaction curves by use of an OTU definition of 97% sequence similarity.”
MethodAntibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197 · cited 1×
“Diarrhea is a common side effect of the administration of antibiotics, with Clostridium difficile being responsible for most of the severe cases of antibiotic-associated diarrhea (AAD), including the development of pseudomembranous colitis [1].”
BackgroundMcFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872 · cited 1×
“difficile antibiotics or the administration of probiotic organisms— have been tried for treatment of RCD [12, 13] [14].”
BackgroundKyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804 · cited 1×
“difficile toxin [11].”
Breaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724 · cited 1×
“difficile antibiotics or the administration of probiotic organisms— have been tried for treatment of RCD [12, 13] [14].”
BackgroundAas, J., Gessert, C. E., & Bakken, J. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367657 · Cited by 518 · cited 1×
“individuals to patients with RCD [4, 15]—is to alter the patient’s microbiome and to restore colonization resistance.”
BackgroundBACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS
Tvede, M., & Rask-Madsen, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92749-9 · Cited by 491
Vollaard, E. J., & Clasener, H. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.409 · Cited by 478 · cited 1×
“microbiota is that of “colonization resistance” [10].”
Cited by
Items 701–800 of 999
Therapeutic Approaches for Clostridium difficile Infections
Marsh, J. W., & Curry, S. R. (2013) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc09a03s30 · Cited by 8
Tschoeke, D. A., de Oliveira, L. S., Leomil, L., Tanuri, A., & Thompson, F. L. (2017) · BMC Medical Genomics · doi:10.1186/s12920-016-0242-1 · Cited by 8
Shi, W., Hu, Y., Zheng, X., Ning, Z., Wu, M., Xia, F., Prast‐Nielsen, S., Hu, Y. O. O., & Xu, B. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0981-9 · Cited by 13
Treatment of Severe and Fulminnant Clostridioides difficile Infection
Cheng, Y., & Fischer, M. (2019) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-019-00262-1 · Cited by 9
Mehta, S. R., & Yen, E. F. (2020) · Translational research · doi:10.1016/j.trsl.2020.11.013 · Cited by 9
Cho, Y., Kim, J., Pai, H., & Rho, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.919907 · Cited by 8
The role of the human microbiome in otolaryngology–head and neck surgery: A contemporary review
Hong, P., Liu, C. M., Nordstrom, L., & Lalwani, A. K. (2013) · The Laryngoscope · doi:10.1002/lary.24490 · Cited by 8
“reduction in bacterial diversity in the intestine has been associated with recurrent Clostridium difficile infections.(3) Altered microbiota composition has also been associated with inflammatory bowel disease,(4) necrotizing enterocolitis,(5) and irritable bowel syndrome.”
BackgroundThe Microbiota and infectious diarrhea
Surawicz, C. M. (2010) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(10)70018-x · Cited by 11
“in those who developed rCdi, there was a significant and consistent decrease in phylogenetic richness of the flora compared to controls and to those with CDI who did not develop recurrences [47] (Fig.”
BackgroundResultMikrobiom und entzündliche Darmerkrankungen
Autenrieth, D., & Baumgart, D. C. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-111608 · Cited by 10
Le transfert de flore digestive : une revue de la littérature
Barbut, F., Collignon, A., Butel, M. J., & Bourlioux, P. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.05.004 · Cited by 13
AMPs and Mechanisms of Antimicrobial Action
Furci, L., & Secchi, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814319-3.00006-4 · Cited by 7
Haley, B. J., Pettengill, J., Gorham, S., Ottesen, A., Karns, J. S., & Kessel, J. A. S. V. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00691 · Cited by 10
Saeed, A., Batra, N., Rezgui, R., Alshaghdali, K., Alkhalaf, I., Yadav, D. K., & Dey, P. (2024) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2024.103374 · Cited by 7
Fecal Microbiota Therapy: Ready for Prime Time?
Rao, K. K., Young, V. B., & Aronoff, D. M. (2013) · Infection Control and Hospital Epidemiology · doi:10.1086/674395 · Cited by 7
Self-citationComan, M. M., Bonaventura, M. V. M. D., Cifani, C., Silvi, S., & Verdenelli, M. C. (2023) · Microorganisms · doi:10.3390/microorganisms11040924 · Cited by 9
“Low diversity was seen in patients with recurrent Clostridium difficile infections, while high diversity in the gut microbiota appeared to be related with good health [36,37].”
BackgroundDrapkina, O. M., Лазебник, Л. Б., Бакулин, И. Г., Журавлева, М. С., Бакулина, Н. В., Васильевна, С. Е., Sitkin, S. I., Skalinskaya, M. I., Solovyeva, O. I., Eremina, E. Y., et al. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-210-2-4-32 · Cited by 7
Duo, H., Yang, Y., Zhang, G., Chen, Y., Cao, Y., Luo, L., Pan, H., & Ye, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1430724 · Cited by 7
“…not only prone to relapse of C. dif fi cile after discontinuation of antibiotics but also leading to low microbial diversity (i.e., dysbiosis) due to antibiotic exposure, impairing colonization resistance, which is a major function of a healthy microbiome (Chang et al., 2008; Seekatz et al., 2015).”
BackgroundClostridium difficile and gut health: Bacteria, the gut microbiome, and diet
Yang, H., Wang, L., Villafuerte-Gálvez, J., Ma, X., Xu, H. J., Wu, S., Yao, J., Chen, X., & Cao, Y. (2024) · iMetaOmics. · doi:10.1002/imo2.50 · Cited by 9
“In 2008, Chang et al. reported significantly lower fecal microbial diversity in CDI patients compared to healthy individuals ( p = 0.0154) [87].”
InfluentialPatients as Patches: Ecology and Epidemiology in Healthcare Environments
Lofgren, E., Egizi, A., & Fefferman, N. H. (2016) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2016.224 · Cited by 7
“These findings align perfectly with Clostridium difficile infection, which is driven not necessarily by the presence of the pathogen but rather by the pathogen’s relative abundance compared to other organisms within the patient’s microbiome.(40,41) Interventions meant to alter microbial abundance, such as the use of f…”
ResultBarfuss, S. B., Knackstedt, E. D., Jensen, K., Molina, K. M., & Lal, A. K. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12983 · Cited by 8
Technical pitfalls that bias comparative microbial community analyses of aquatic disease Ian Hewson*
Hewson, I. (2019) · Diseases of Aquatic Organisms · doi:10.3354/dao03432 · Cited by 7
Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile
Sánchez-Pellicer, P., Navarro‐López, V., González-Tamayo, R., Llopis-Ruiz, C., Núñez-Delegido, E., Ruzafa-Costas, B., Navarro-Moratalla, L., & Agüera-Santos, J. (2021) · Microorganisms · doi:10.3390/microorganisms9081727 · Cited by 8
“This is a frequent finding in patients with CDI [18] and has also been observed in colonized subjects by C.”
BackgroundGomez‐Simmonds, A., Annavajhala, M. K., Nunez, M. P., Maćešić, N., Park, H., & Uhlemann, A. (2022) · mSphere · doi:10.1128/msphere.00361-22 · Cited by 9
Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient
Porto, D. L., Mularoni, A., Castagnola, E., & Saffioti, C. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14159 · Cited by 8
“8,71 For this reason, microbiota restoration therapy (MRT) or FMT are potentially valuable options for the treatment of rCDI.”
BackgroundDual stressors of infection and warming can destabilize host microbiomes
Li, J., Gao, Y. Y., Stevens, E. J., & King, K. C. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0069 · Cited by 7
“For example, Clostridioides difficile infection in the human gut can decrease microbiome diversity [19], while Mycobacterium tuberculosis infection has the opposite effect [20,21].”
BackgroundTherapeutic Potential of the Human Gastrointestinal Microbiome
Borody, T. J., Peattie, D. A., & Campbell, J. (2013) · Drug Development Research · doi:10.1002/ddr.21093 · Cited by 8
“In addition, the varied microbial deficiencies present in different gut dysbioses and individuals [Tvede and Rask-Madsen, 1989; Chang et al., 2008; Khoruts et al., 2010; Petrof et al., 2013] means that tailoring cultured replacements could prove challenging.”
BackgroundFecal microbiota transplantation for management of Clostridium difficile infection
Vaishnavi, C. V. (2014) · Indian Journal of Gastroenterology · doi:10.1007/s12664-014-0459-x · Cited by 10
“The mechanism of action may be the restoration of missing components of the flora including Bacteroidetes and Firmicutes in patients with recurrent CDI [27, 28].”
BackgroundMicrobiota intestinal: sus repercusiones clínicas en el cuerpo humano
Gigliotti, N. (2013) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2013.523 · Cited by 10
Shin, J. H., & Warren, C. A. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1323616 · Cited by 7
“The diversity of the intestinal microbiota is lower in patients with CDI compared with healthy patients, and is decreased further in recurrent episodes.(12) Antibiotic treatment changes the composition”
BackgroundTran, V., Phan, J., Nulsen, B., Huang, L., Kaneshiro, M., Weiss, G. A., Ho, W. W., Sack, J. L., Ha, C. Y., Uslan, D. Z., et al. (2018) · ACG Case Reports Journal · doi:10.14309/crj.2018.97 · Cited by 9
“Multiple CDI recurrences are associated with increasing loss of microbial diversity.(1) Studies show that FMT has a roughly 90% success rate in preventing recurrence of CDI.”
BackgroundArgueta, P. P., Salazar, M. J., Attar, B. M., Simons-Linares, C. R., & Shen, B. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa224 · Cited by 10
Bernard, R., Hourigan, S. K., & Nicholson, M. R. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab056 · Cited by 8
Gastrointestinal Microbial Ecology With Perspectives on Health and Disease
Spohn, S. N., & Young, V. B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00032-3 · Cited by 12
Self-citationLactic Acid Bacteria and the Human Gastrointestinal Tract
Kwok, L. Y. (2014) · Springer eBooks · doi:10.1007/978-94-017-8841-0_6 · Cited by 11
Shin, J. H., Pawlowski, S. W., & Warren, C. A. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1966255 · Cited by 7
“difficile,(28) a lower microbiome diversity is considered one of the factors predisposing to CDI, and has been associated with recurrences.(29) However, it has been shown in human studies that the microbiome diversity generally tends to be higher in older individuals.”
BackgroundOxygen and Metabolism: Digesting Determinants of Antibiotic Susceptibility in the Gut
Heinzinger, L. R., Johnson, A., Wurster, J. I., Nilson, R., Penumutchu, S., & Belenky, P. A. (2020) · iScience · doi:10.1016/j.isci.2020.101875 · Cited by 6
“Antibiotic-induced dysbiosis specifically decreases diversity of the gut microbiome and creates a nutrient niche vacuum that allows opportunistic pathogens to colonize and cause local infections (Dollive et al., 2013; Blaser and Falkow 2009; Chang et al., 2008).”
BackgroundFeuerstadt, P., & LaPlante, K. L. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002582 · Cited by 10
Making waves: From tap to gut- exploring the impact of drinking water on gut microbiota
Moghaddam, H. S., Abkar, L., & Fowler, J. (2024) · Water Research · doi:10.1016/j.watres.2024.122503 · Cited by 6
Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections
Lee, A., Yoo, J. S., & Yoon, E.-J. (2024) · Antibiotics · doi:10.3390/antibiotics13100995 · Cited by 9
“Disruption in gut microbiota weakens the intestinal defense owing to the healthy microbiota and makes the gastrointestinal tract susceptible to foreign pathogens including C. difficile [68–70].”
BackgroundKhanna, S., Yoho, D. S., Handel, D. V., Clark, B. J., Awad, T., Guthmueller, B., Armandi, D., Knapple, W., Safdar, N., Baggott, B. B., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251339697 · Cited by 12
Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection: What’s Old Is New Again?
Suwantarat, N., & Bobak, D. A. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0314-8 · Cited by 7
Koya, V., Campbell, A. M., McLaughlin, P. J., Tewari, D., Wilson, R. P., & Cooper, T. K. (2012) · Veterinary Pathology · doi:10.1177/0300985811429809 · Cited by 7
“difficile–associated diarrhea.(2,9) Note, however, that despite a relative high incidence of murine Helicobacter spp.”
BackgroundYan, D., Huang, Y., Chen, Y., Lv, T., Zhu, C., Huang, J., & Li, L. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.03.004 · Cited by 6
Pediatric Fecal Microbiota Transplantation in Recurrent Clostridioides Difficile
Parnell, J. M., Nicholson, M. R., Kellermayer, R., & Kahn, S. A. (2021) · Pediatric Annals · doi:10.3928/19382359-20211111-01 · Cited by 5
Kim, M. H., Kim, Y. C., Kim, J. L., Park, Y. S., & Kim, H. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07085-z · Cited by 6
Chan, A. A., Flores, E. A., Navarrete, M. S., Tran, D. P., Lee, D. J., & Miller, L. G. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac141 · Cited by 6
“Human microbiota disturbances have a role in susceptibility to other infectious diseases such as Clostridioides difficile–associated diarrhea [10, 11].”
BackgroundWhole-Genome Sequencing Reveals Age-Specific Changes in the Human Blood Microbiota
Lee, E., Sung, J., Kim, H., & Kim, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060939 · Cited by 9
“A decrease in diversity in several studies, including ours, implies a general trend in the aging process [45] as well as highlights diversity as a major factor for promoting the stability of organ systems.”
BackgroundHay, M., Hinsu, A., KORINGA, P. G., Pandit, R. J., Liu, P., Parekh, M. J., Jakhesara, S. J., Dai, X., Crotta, M., Fosso, B., et al. (2023) · Frontiers in Microbiomes · doi:10.3389/frmbi.2023.1301609 · Cited by 9
“…by its association with several human diseases, including chronic autoimmune conditions of the gut (Ott et al., 2004; Manichanh et al., 2006; Willing et al., 2010), recurrent Clostridium dif fi cile infection (Chang et al., 2008) and even increased frailty in old age (Jackson et al., 2016).”
Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection
Suwantarat, N., & Bobak, D. A. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0155-7 · Cited by 9
Present and past perspectives on Clostridium difficile infection
Álvarez-Hernández, D. A., González-Chávez, A., Hermosillo-Cornejo, D. G., Kelly, G. A. F., Díaz-Girón-Gidi, A., & Vázquez-López, R. (2017) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2017.07.016 · Cited by 6
Bezlotoxumab for the prevention ofClostridium difficilerecurrence
Couture-Cossette, A., Carignan, A., Ilangumaran, S., & Valiquette, L. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1363886 · Cited by 6
Sattler, M. M., & Crews, J. D. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab079 · Cited by 6
Clinical Parasitology and Parasitome Maps as Old and New Tools to Improve Clinical Microbiomics
Pane, S., Ristori, M. V., Gardini, S., russo, A., CHIERICO, F. D., & Putignani, L. (2021) · Pathogens · doi:10.3390/pathogens10121550 · Cited by 6
“difficile infections are characterized by almost monomicrobial bacterial distributions of the fecal microbiota [99].”
BackgroundMcFarland, L. V., Goldstein, E. J. C., & Kullar, R. (2023) · Microorganisms · doi:10.3390/microorganisms11061534 · Cited by 7
“Early studies found decreased diversity (less Bacteroidetes and Firmicutes ) in patients with recurrent CDI [21].”
BackgroundDaharsh, L., Lohani, S. C., Ramer‐Tait, A. E., & Li, Q. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1404353 · Cited by 7
Bryant, J. A., Straub, T. J., Pardi, D. S., Litcofsky, K. D., Kelly, C. R., Chafee, M. E., Cohen, S. H., Khanna, S., Berenson, C. S., Wortman, J. R., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf408 · Cited by 5
Fortman, D. D., Avellan, M. G. P., Hurd, D. E., Schwartz, M. B., Dubner, H. M., Hewitt, C., Berton, S., Ernst, S. J., Rose, A. E., Wangd, H. Z. H., et al. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000871 · Cited by 6
Zhang, J., Ren, G., Li, M., Lu, P., & Yi, S. (2019) · Case Reports in Hematology · doi:10.1155/2019/4505238 · Cited by 5
Gonzales-Luna, A. J., & Carlson, T. J. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-00729-8 · Cited by 5
Fidaxomicin for the Treatment of Clostridioides Difficile in Children
Skinner, A. M., Scardina, T. L., & Kociolek, L. K. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0104 · Cited by 5
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
Oliver, M. B., & Vaughn, B. P. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s273318 · Cited by 5
“The pathogenesis of rCDI is mediated by ongoing dysbiosis and failure of the hosts microbiota diversity of and function to return.(29) As dysbiosis is an essential component of CDI, the presence of C.”
BackgroundAllegretti, J. R., Khanna, S., & Feuerstadt, P. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002463 · Cited by 6
“Through a proprietary ethanol-based puri fi cation process, essentially all elements (including viruses, vegetative bacteria, parasites, fungal organisms) are removed from the sample, except spore-forming Firmicutes.”
BackgroundInfluentialQuera, R., Paulina Núñez, F., von Mühlenbrock, C., & Espinoza, R. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2024.03.004 · Cited by 9
Treatment ofClostridium difficileinfection: recent trial results
Lewis, S. S., & Anderson, D. J. (2013) · Clinical Investigation · doi:10.4155/cli.13.72 · Cited by 5
New and emerging therapies in treatment of Clostridium difficile infection
Goyal, H., Perisetti, A., Rehman, M., & Singla, U. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001103 · Cited by 9
Biodiversity–ecosystem function relationships on bodies and in buildings
Dunn, R. R., Reese, A. T., & Eisenhauer, N. (2018) · Nature Ecology & Evolution · doi:10.1038/s41559-018-0750-9 · Cited by 5
Razim, A., Pacyga-Prus, K., Martirosian, G., Szuba, A., Gamian, A., Myc, A., & Górska, S. (2019) · Microorganisms · doi:10.3390/microorganisms7110565 · Cited by 5
“The bacteria becomes dangerous when the both qualitative and quantitative composition of gut microbiota is distressed [3]; usually as a result of the antibiotic such as clindamycin, cephalosporins or fluoroquinolones treatment [4].”
BackgroundLights and Shadows of Microbiota Modulation and Cardiovascular Risk in HIV Patients
Villoslada-Blanco, P., Pérez‐Matute, P., & Oteo, J. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18136837 · Cited by 8
Fecal Microbiota Transplantation
Borody, T. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54843-4.00018-0 · Cited by 7
Gholam-Mostafaei, F. S., Azimirad, M., Naseri, K., Nabavi-Rad, A., Aghdaei, H. A., Shahrokh, S., Daryani, N. E., Yadegar, A., & Zali, M. R. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1147945 · Cited by 8
Exploring Human Bacterial Diversity Toward Prevention of Infectious Disease and Health Promotion
Yousuf, B., & Mishra, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814849-5.00029-0 · Cited by 7
Gut Microbiology – A Relatively Unexplored Domain
Brooks, S. P. J., Green-Johnson, J. M., Inglis, G. D., Uwiera, R. R. E., & Kalmokoff, M. L. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-088504-9.00303-2 · Cited by 6
Genomic and systems approaches to translational biomarker discovery in immunological diseases
MacIsaac, K. D., Wang, I., Menetski, J. P., & Roberts, C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.002 · Cited by 5
Fecal Microbiota Transplantation: What We Know and What We Need to Know
Surawicz, C. M. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0609 · Cited by 6
“Abnormal microbiota in recurrent CDI was demonstrated in studies of the fecal microbiome in 3 healthy persons and 7 with CDI, of whom 3 developed recurrent CDI (10).”
BackgroundFaecal microbiota transplantation: past, present and future
Brandt, L. J. (2017) · The Medical Journal of Australia · doi:10.5694/mja17.00372 · Cited by 5
Hou, M., Li, C.-L., Moi, S., Chen, F.-M., Chen, J.-Y., Shih, S., Kan, J., Yang, S., & Chiang, C.-P. (2026) · Communications Medicine · doi:10.1038/s43856-026-01384-1 · Cited by 5
Tang, Z.-W., Zhang, C.-E., Ma, F.-Z., Cui, Y., Ye, R.-H., Pu, S.-B., & Ma, Z. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.105973 · Cited by 4
van Rossen, T. M., van Beurden, Y. H., Bogaards, J. A., Budding, A. E., Mulder, C. J. J., & Vandenbroucke‐Grauls, C. M. J. E. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09506-7 · Cited by 7
The role of the gut microbiota in patients with Kleefstra syndrome
Bloemendaal, M., Vlaming, P., de Boer, A., Vermeulen, K., Bouman, A., Kleefstra, T., & Vásquez, A. A. (2023) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32926 · Cited by 7
“Moreover, it is found in studies on obesity (Ley, Turnbaugh, Klein, & Gordon, 2006), recurrent antibiotic induced Clostridium difficile infection (Chang et al., 2008) and ulcerative colitis (Lepage et al.”
BackgroundEuropean Practice for CDI Treatment
Fitzpatrick, F., Brennan, R., van Prehn, J., Skally, M., Brady, M., Burns, K., Rooney, C. M., & Wilcox, M. H. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-42108-2_4 · Cited by 8
Next -generation probiotics as potential therapeutic supplement for gastrointestinal infections
Gupta, N., Kachhawaha, K., Behera, D. K., & Verma, V. K. (2023) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2024.100002 · Cited by 5
Sehgal, K., & Feuerstadt, P. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1399440 · Cited by 9
Human Microbiome: Implications on Health and Disease
Hira, P., Sood, U., Gupta, V., Nayyar, N., Mahato, N. K., Singh, Y. P., Lal, R., & Shakarad, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-4298-0_8 · Cited by 5
Exploring ways to improve CDI outcomes
Galpérine, T., & Guery, B. P. (2018) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2017.10.009 · Cited by 4
The Impact of Genetics on Gut Microbiota of Growing and Fattening Pigs under Moderate N Restriction
Sarri, L., Costa-Roura, S., Balcells, J., Seradj, A. R., & de la Fuente, G. (2021) · Animals · doi:10.3390/ani11102846 · Cited by 4
“Higher bacterial diversity is generally considered favorable in terms of stability and resilience to dysbiosis and potential pathogen threats [37].”
BackgroundFrost, F. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01395-9 · Cited by 6
Taghaddos, D., Saqib, Z., Bai, X., Berčík, P., & Collins, S. M. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.03.008 · Cited by 13
Deane, J., Rea, M. C., Fouhy, F., Stanton, C., Ross, R. P., & Plant, B. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802304-4.00011-6 · Cited by 7
Gunaratnam, S., Diarra, C., Paquette, P. D., Ship, N. J., Millette, M., & Lacroix, M. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-020-09729-5 · Cited by 7
Clostridium difficileinfection: still principally a disease of the elderly
Diggs, N. G., & Surawicz, C. M. (2010) · Therapy · doi:10.2217/thy.10.17 · Cited by 5
Gastrointestinal Infections After Solid Organ or Hematopoietic Cell Transplantation
Damman, C. J., & McDonald, G. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-28797-3_19 · Cited by 4
Clinical laboratory utilization management and improved healthcare performance
Naugler, C. T., & Church, D. L. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1526164 · Cited by 4
Midtvedt, T., Norin, E. L., Benno, P., & Dahlgren, A. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.280 · Cited by 4
Sharpton, T. J., & Gaulke, C. A. (2015) · mBio · doi:10.1128/mbio.01367-15 · Cited by 4
“September/October 2015 Volume 6 Issue 5 e01367-15 ® mbio.asm.org 1 decrease in the abundance of Lachnospiraceae and Barnesiella (4), while microbiome transplantations are instead associated with a bloom in Bacteroidetes (5).”
BackgroundDevelopment of an In Vitro Fermentation Model to Culture the Human Distal Gut Microbiota
McDonald, J. A. K. (2013) · The Atrium (University of Guelph) · Cited by 8
Emergence of antibiotic resistance in gut microbiota and its effect on human health
Kumar, M., Sharma, A., Verma, A., & Shrivastava, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91313-3.00002-7 · Cited by 4
Khanna, S., Yoho, D. S., Handel, D. V., Clark, B. J., Awad, T., Guthmueller, B., Armandi, D., Knapple, W., Safdar, N., Baggott, B. B., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251396744 · Cited by 5
Zilinger, A., Sramek, M. K., Chandra, T., Schmidt, T., Bagel, J., Stayduhar, A., Fryer, J., & Sunvold, G. D. (2026) · Pets · doi:10.3390/pets3010001 · Cited by 3
“In humans, decreased microbial diversity is associated with increased C. difficile infection and inflammatory bowel disease, as well as reduced cognition [88–90].”
Self-citationThe human microbiome at translational crossroads: an ecological and causal perspective
Wong, S. H. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2026-102 · Cited by 3
“[10] This success has culminated in the regulatory approval of microbiome‑derived live biotherapeutic products (LBPs), such as Rebyota and Vowst.”
Lagounova, M., MacNicol, J. L., Weese, J. S., & Pearson, W. (2023) · Animals · doi:10.3390/ani13142344 · Cited by 3
Metadata
- Authors
- Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B.
- Affiliations
- Michigan State University (US)
- Corresponding author
- Young, Vincent B.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02
- Volume
- 197
- Issue
- 3
- Pages
- 435-438
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2139607253
- Cited by
- 1,010
- References
- 15
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 36 · 2023: 54 · 2022: 42 · 2021: 57 · 2020: 69 · 2019: 59 · 2018: 107 · 2017: 78 · 2016: 77 · 2015: 88 · 2014: 87 · 2013: 78 · 2012: 53
- FWCI
- 17.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile, fecal microbiota, microbial diversity, antibiotic-associated diarrhea, 16S rRNA gene sequencing, bacterial community composition, dysbiosis, microbiota restoration
- MeSH terms
- Anti-Bacterial Agents, Diarrhea, Drug Administration Schedule, Enterocolitis, Pseudomembranous, Feces, Female, Humans, Male, Phylogeny, Recurrence, Reference Values, Genetic Variation, Clostridioides difficile
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.